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Abstract
Epidemiologic evidence has linked chronic exposure to inorganic arsenic (iAs) with an increased
prevalence of diabetes mellitus. Laboratory studies have identified several mechanisms by which
iAs can impair glucose homeostasis. We have previously shown that micromolar concentrations of
arsenite (iAsIII) or its methylated trivalent metabolites, methylarsonite (MAsIII) and
dimethylarsinite (DMAsIII), inhibit the insulin-activated signal transduction pathway, resulting in
insulin resistance in adipocytes. Our present study examined effects of the trivalent arsenicals on
insulin secretion by intact pancreatic islets isolated from C57BL/6 mice. We found that 48-hour
exposures to low subtoxic concentrations of iAsIII, MAsIII or DMAsIII inhibited glucose-
stimulated insulin secretion (GSIS), but not basal insulin secretion. MAsIII and DMAsIII were
more potent than iAsIII as GSIS inhibitors with estimated IC50≤0.1 μM. The exposures had little
or no effects on insulin content of the islets or on insulin expression, suggesting that trivalent
arsenicals interfere with mechanisms regulating packaging of the insulin transport vesicles or with
translocation of these vesicles to the plasma membrane. Notably, the inhibition of GSIS by iAsIII,
MAsIII or DMAsIII could be reversed by a 24-hour incubation of the islets in arsenic-free medium.
These results suggest that the insulin producing pancreatic β-cells are among the targets for iAs
exposure and that the inhibition of GSIS by low concentrations of the methylated metabolites of
iAs may be the key mechanism of iAs-induced diabetes.
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Introduction
Arsenic (As) is a naturally occurring toxic metalloid commonly found in ground and surface
water reservoirs. Tens of millions of people worldwide are currently exposed to high levels
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of inorganic arsenic (iAs) in drinking water (BGS and DPHE, 2001; The World Bank,
2005). At least 13 million U.S. residents drink water containing iAs at levels higher than the
current EPA maximum contaminant level of 10 μg As/L (ATSDR, 2007). Although the
focus of public health and regulatory agencies has traditionally been on the carcinogenic
effects of iAs, epidemiological evidence suggests that even greater numbers of people
exposed to iAs are at risk of developing non-cancerous diseases, including diabetes mellitus.
A panel of experts assembled by the NIEHS National Toxicology Program (NTP) in January
2011 agreed that existing data in humans support an association between diabetes and high
exposures to iAs in drinking water (≥150 ppb As); however, the evidence is insufficient to
conclude that diabetes is associated with low-to-moderate exposures (<150 ppb As) (Maull
et al., 2012). This panel also concluded that the animal and in vitro studies implicate several
pathways by which iAs can influence pancreatic β-cell function and insulin sensitivity.
Diabetes associated with iAs exposure has been historically referred to as type 2 diabetes
(Longnecker and Daniels, 2001; Maull et al., 2012; Navas-Acien et al., 2006). However,
little information has been provided on the mechanisms underlying this disease. We have
shown that subtoxic micromolar concentrations of arsenite (iAsIII) and its methylated
trivalent metabolites, methylarsonite (MAsIII) and dimethylarsinite (DMAsIII), inhibit the
insulin-dependent phosphorylation of PKB/Akt by PDK, thus suppressing the insulin-
stimulated glucose uptake in adipocytes (Paul et al., 2007a, 2008; Walton et al., 2004).
DMAsIII did not inhibit PKB/Akt phosphorylation, but interfered with insulin signaling
downstream from PKB/Akt. While these results are consistent with insulin resistance
typically associated with type 2 diabetes, other studies have shown that iAs can also target
the mechanisms regulating glucose-stimulated insulin secretion (GSIS) by pancreatic β-
cells.
GSIS is a biphasic process (Rorsman et al., 2000). The 1st phase is initiated by the uptake
and oxidative metabolism of glucose, resulting in an increased production of ATP and
depolarization of plasma membrane, followed by influx of extracellular calcium ions and
activation of Ca2+-dependent calmodulin protein kinases that phosphorylate proteins
associated with insulin secretory vesicles, the ion channels, and the cytoskeletal structure.
The 2nd phase of GSIS involves an ATP-dependent mobilization of storage pool granules to
the cell surface to sustain insulin release. Results of previous studies suggest several
mechanisms by which iAs could interfere with GSIS: (i) Like glucose, iAsIII is transported
across the plasma membrane by GLUT transporters (Liu et al., 2006) and thus, could
compete with glucose uptake by β-cells. (ii) iAsIII modulates expression of hexokinase, the
enzyme that helps to control flux of glucose-6-phosphate into glycolysis (Pysher et al.,
2007). (iii) iAsIII forms a stable complex with dihydrolipoamide, a cofactor of pyruvate
dehydrogenase and α-ketoglutarate dehydrogenase, the key enzymes in the oxidative
metabolism of glucose (Tsen, 2004). (iv) iAsIII inhibits calpain-10 (Díaz-Villaseñor et al.,
2008), the Ca2+-dependent protease that activates SNAP-25 (a member of the insulin
secretory machinery) (Turner, 2007). (v) Finally, arsenate (iAsV), the product of iAsIII
oxidation, can interfere with ATP synthesis by replacing phosphate in the reactions of
oxidative phosphorylation in mitochondria (Gresser, 1981). Another mechanism has been
proposed by a recent study using rat insulinoma (INS-1) cells. Here, exposure to iAsIII was
shown to provoke an adaptive oxidative stress response that increased antioxidant levels and
dampened signaling involving reactive oxygen species that is thought to be essential for
regulation of GSIS (Fu et al., 2010).
Notably, all the above studies examined only effects of iAs species, iAsIII and iAsV. In
addition, most of these studies used insulinoma cell lines which differ from the insulin
secreting pancreatic islets by their morphology, level of differentiation, insulin content and,
most importantly by their abnormal response to glucose stimulation. The present study used
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intact isolated pancreatic islets to compare the effects of iAsIII with effects of its methylated
trivalent metabolites, MAsIII and DMAsIII, which are more reactive and more toxic than
either iAsIII or iAsV (Styblo et al., 2000, 2002; Thomas et al., 2001). Our results show that
both MAsIII and DMAsIII are more potent than iAsIII as inhibitors of GSIS and that the




Pancreatic islets were isolated from adult male C57BL/6 mice (Charles River Laboratories,
Wilmington, MA). All procedures involving mice were approved by the University of North
Carolina Institutional Animal and Use Committee. Mice were sacrificed by cervical
dislocation and pancreas was infused in situ with collagenase P (1 mg/ml, Roche
Diagnostics Corp., Indianapolis, IN) via the common bile duct. Pancreas was then removed
and digested in the collagenase solution for 12 min at 37 °C. The digestate was washed and
islets were purified by centrifugation in a gradient of Ficoll PM 400 (GE Healthcare,
Uppsala, Sweden) (Szot et al., 2007).
Treatment
The isolated islets were cultivated overnight at 37 °C with 5% CO2 in RPMI 1640 medium
(Mediatech, Manassas, VA) with 10% fetal bovine serum, 10 mM Hepes, 1 mM sodium
pyruvate, 100 U/ml penicillin, and 100 μg/ml streptomycin (all from Sigma-Aldrich, St.
Louis, MO). The same medium was used in experiments in which the islets were exposed to
iAsIII (sodium arsenite; Sigma-Aldrich), MAsIII (methylarsine oxide) or DMAsIII
(iododimethylarsine). MAsIII and DMAsIII were provided by Dr. William Culllen
(University of British Columbia, Vancouver, Canada). To limit oxidation of trivalent
arsenicals, the culture medium was replaced every 24 h with medium containing freshly
prepared arsenicals.
Speciation analysis of As
The concentrations and metabolism of arsenicals in the islets were monitored by hydride
generation (HG)-cryotrapping (CT)-inductively coupled plasma-mass spectrometry (ICP-
MS), using Agilent 7500cx ICP-MS system (Agilent Technologies, Santa Clara, CA) and
the HG-CT components and procedures previously described for HG-CT-atomic absorption
spectrometry (AAS) technique for speciation analysis of As in biological samples
(Hernández-Zavala et al., 2008; Matoušek et al., 2008) (see Supplementary Materials for
details).
Static GSIS assay
Islets exposed to arsenicals or control, unexposed islets (15 islets/assay) were transferred
into a glucose-free buffer containing 114 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.16
mM MgSO4, 20 mM Hepes, 2.5 mM CaCl2, 0.2% bovine serum albumin, and 25.5 mM
NaHCO3 (all from Sigma-Aldrich) for 1 h at 37 °C and 5% CO2, followed by a 1-hour
incubation with 2.5 mM glucose (Sigma-Aldrich) and 1-hour incubation with 16.7 mM
glucose (Boucher et al., 2004). Medium from each incubation step was frozen and stored for
insulin analysis. Insulin concentrations were determined using Rat/Mouse Insulin ELISA kit
from Millipore (Billerica, MA). The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide (MTT) assay (Styblo et al., 2002) was used to monitor islet viability.
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Islet RNA was extracted using RNEasy Micro kit with on column DNAse treatment
(Qiagen, Valencia, CA), and analyzed by a Nanodrop 2000c spectrophotometer
(ThermoScientific, Waltham, MA). cDNA was prepared using random primers and
Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA). The transcripts of two
mouse insulin genes (Ins1 and Ins2) and 18S RNA were quantified using the corresponding
Taqman assays with Fast Universal PCR master mix (Applied Biosystems, Foster City, CA)
and Lightcycler 480 II instrument and software 1.5.0 (Roche).
Statistical analysis
Data were analyzed by ANOVA and Fisher’s PLSD tests using StatView 5.0.1 software
(SAS institute, Cary, NC). Data are represented as mean±standard error (SE). Differences
between treatments with p<0.05 were considered statistically significant.
Results and discussion
The iAs-induced diabetes has been referred to as type 2 diabetes because of the adult onset
of the disease and absence of ketoacidosis which is typically associated with type 1 diabetes
(Haller et al., 2005). The onset and early stages of type 2 diabetes are characterized by
insulin resistance, i.e., nonresponsiveness to insulin signaling leading to impaired uptake of
glucose in peripheral tissues, and hyperinsulinemia due to a compensatory increase of
insulin production by β-cells. The continued insulin resistance ultimately leads to the
pancreatic β-cell failure (Prentki and Nolan, 2006). However, results of our recent
laboratory and population studies suggest that the phenotype of diabetes associated with iAs
exposure may differ from that of type 2 diabetes. Specifically, we have shown that exposure
of C57Bl/6 mice to iAs alone or combined with high-fat diet produced diabetes which is
characterized by low insulin resistance (HOMA-IR) and impaired insulin production in
response to glucose challenge (Paul et al., 2007b, 2011). Similarly, we found negative
correlations between iAs exposure and fasting plasma insulin and HOMA-IR among
residents of the Zimapan and Lagunera regions in Mexico who drank water containing iAs
(up to 215 μg As/L) (Del Razo et al., 2011). Taken together these data point to β-cells as a
primary target for the diabetogenic effects of iAs exposure and to an impaired GSIS as the
key mechanism of iAs-induced diabetes. The present study used pancreatic islets isolated
from C57Bl/6 mice to examine effects of iAs and its toxic methylated trivalent metabolites
on GSIS.
The islets used in this study were fully functional as documented by a strong response to
glucose stimulation, i.e., 10–15-fold increase in insulin secretion by control (untreated) islets
treated with 16.7 mM glucose (Fig. 1A). Exposures to low sub-micromolar or micromolar
concentrations of trivalent arsenicals for 48 h significantly decreased GSIS in islets
stimulated with 16.7 mM glucose, but had no effects on basal insulin secretion by islets
incubated with 2.5 mM glucose. Notably, MAsIII, and particularly DMAsIII were more
potent than iAsIII as GSIS inhibitors, decreasing insulin secretion by >50% at the
concentration of 0.1 μM. These exposures, however, did not affect the total insulin content
in the culture; i.e., the amount of insulin secreted in response to glucose stimulation plus the
amount of insulin remaining in the stimulated islets (Fig. 1B). Results of a previous study
using primary rat β-cells have suggested that a 144-hour exposure to cytotoxic 5 μM iAsIII
suppresses insulin expression (Díaz-Villaseñor et al., 2006). In the present study, the 48-
hour exposure to 2 μM iAsIII that significantly inhibited GSIS had no effects on Ins1 or Ins2
mRNA levels (Fig. 1C). Similarly, 0.5 μM MAsIII and 1 μM DMAsIII decreased Ins1 and/or
Ins2 mRNA levels only by small (~20%) margins. The concentrations of arsenicals used in
this study did not decrease islet viability (Fig. 1D), indicating that the GSIS impairment was
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not due to loss of β-cell integrity. Taken together, these results suggest that subchronic
exposures to trivalent arsenicals inhibit GSIS by interfering with mechanisms that regulate
the assembly and/or secretion of insulin vesicles, but have little effects on de novo insulin
synthesis. Consistent with this mode of action were results obtained after treatment of AsIII-
exposed and glucose-stimulated islets with KCl. KCl is an insulin secretagogue that
depolarizes β-cell membrane and triggers Ca2+ ion influx, thus increasing exocytosis of the
insulin-containing secretory granules independent of glucose stimulation or ATP production
(Liang and Matschinsky, 1994). In this study, KCl treatment overcame the inhibitory effects
of arsenicals in glucose-stimulated islets, resulting in a marked increase in insulin secretion
(Fig. 2).
We have previously reported that mice exposed to iAsIII developed diabetes (Paul et al.,
2007b, 2008, 2011). HG-CT-AAS analyses showed that significant amounts of iAs and its
methylated metabolites, MAs and DMAs, were retained in tissues that regulate glucose
homeostasis, including liver, pancreas, skeletal muscle and fat. Liver is thought to be the
major site for iAs methylation. However, our whole-mouse experiments could not provide
information about the origin of the methylated metabolites found in the pancreas. In this
study, we used HG-CT-ICP-MS to identify As species retained in the islets exposed for 48 h
to 0.5 μM iAsIII, MAsIII or DMAsIII and in control (unexposed) islets (Fig. 3). We found the
total As levels (i.e., sum of As species) to be higher in islets exposed to MAsIII and DMAsIII
as compared to islets exposed to iAsIII. This finding is consistent with results of our previous
studies (Drobná et al., 2005), suggesting that the methylated trivalent arsenicals are taken up
and retained by mammalian cells to a greater extent than iAsIII. The HG-CT-ICP-MS
analysis also showed that murine pancreatic islets are capable of methylating iAsIII and
MAsIII. Specifically, DMAs accounted for ~57% of As in islets exposed to iAsIII or MAsIII.
DMAs was also found in medium in which the islets exposed to iAsIII or MAsIII were
maintained (data not shown). Although we did not determine the oxidation state of As, it is
possible that the inhibition of GSIS in islets exposed to iAsIII or MAsIII is at least in part due
to the formation of DMAsIII. We were able to detect iAs, MAs and DMAs even in control
islets. Because the culture medium contained only traces of iAs (≤0.5 nM), the presence of
these arsenicals in the islets suggests that mice were exposed in vivo to iAs or methylated
arsenicals from diet or the environment. Notably, the control islets contained more iAs but
less MAs and DMAs than did the islets exposed to 0.5 μM iAsIII, suggesting again that the
methylated arsenicals are responsible for GSIS inhibition. Future studies using pancreatic
islets from mice knocked out for As3mt (Hughes et al., 2010), the key enzyme in the
methylation pathway for iAs, will help us to better characterize the potentials of individual
AsIII species to inhibit GSIS.
We have recently reported that chronic exposure to iAs in drinking water is associated with
an increased risk of diabetes in the Zimapan and Lagunera regions in Mexico (Del Razo et
al., 2011). Here, the risk of diabetes was associated only with the current levels of iAs in
drinking water, but not with iAs levels recorded in the local water supplies during previous
years or with cumulative exposure. These findings indicate that iAs-induced diabetes could
be a temporary, possibly reversible condition that lasts only as long as the exposure lasts,
i.e., as long as iAs or its metabolites are present in the target tissues. To test the reversibility
hypothesis in this study, we examined GSIS by isolated pancreatic islets that were exposed
to 2 μM iAsIII, 0.5 μM MAsIII or 0.5 μM DMAsIII for 24 h and then let to recover for
additional 24 h in As-free medium (Fig. 4). The 24-hour exposures inhibited GSIS to
somewhat lesser extent than the 48-hour exposures described in Fig. 1. Notably, we found
that the 24-hour incubation in As-free medium restored GSIS to the levels that were not
significantly different from GSIS in control, unexposed islets. Thus, the inhibition of GSIS
by trivalent arsenical was reversed when the exposure was discontinued. However,
significance of these findings is uncertain. The time of exposure in this study was limited by
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viability of isolated pancreatic islets, which usually do not survive in culture for longer than
4 days after isolation. It is possible that longer exposures would result in permanent changes
and irreversible inhibition of GSIS. Thus, the reversibility of GSIS inhibition by long-term
exposures to trivalent arsenicals needs to be examined in laboratory studies using β-cell
lines and mice or, preferably, in epidemiologic studies involving human populations
chronically exposed to iAs.
In summary, our results show that trivalent arsenicals, and specifically the methylated
trivalent metabolites MAsIII and DMAsIII are potent inhibitors of GSIS by pancreatic islets.
In a broader context, these results provide new evidence that iAs exposure targets pancreatic
β-cells and that inhibition of insulin secretion by these cells is at least in part responsible for
the diabetogenic effects of iAs exposure.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Inhibition of glucose stimulated insulin secretion (GSIS) by trivalent arsenicals: A, GSIS by
pancreatic islets exposed to iAsIII, MAsIII or DMAsIII for 48 h; mean and standard error
(SE) for 4–7 assays with 15 islets per assay are shown (*p<0.05 and **p<0.01 for differences
between exposed and unexposed islets incubated with 2.5 mM or 16.7 mM glucose). B, the
islet insulin content and amount of secreted insulin in unexposed islet cultures (Ctrl.) and
cultures exposed for 48 h to arsenicals and stimulated with 16.7 mM glucose; mean and SE
for 5–9 assays with 15 islets per assay are shown (*p<0.05 for differences between exposed
and unexposed islets). C, Ins1 and Ins2 mRNA levels in islets exposed to trivalent arsenicals
for 48 h and in control islets; mean and SE for 4–8 assays with 15 islets per assay are shown
(*p<0.05 for differences between exposed and control islets). D, viability of islets exposed to
trivalent arsenicals for 48 h and of control islets measured by MTT assay; mean and SE for
4–9 assays with 15 islets per assay are shown.
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Effects of trivalent arsenicals on insulin secretion by pancreatic islets stimulated with 16.7
mM glucose in presence or absence of an insulin secretagogue, KCl (35 mM); mean and
standard error for 4–10 assays with 15 islets per assay are shown (*p<0.05 for differences
between exposed and control (Ctrl), unexposed islets stimulated with 16.7 mM glucose in
absence of KCl; †p<0.0001 for differences between insulin secretion by glucose stimulated
islets in the presence and absence of KCl; §p<0.02 for difference between the glucose
stimulated and KCl-treated islets exposed to 1 μM and 2 μM iAsIII).
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Arsenic species in pancreatic islets exposed for 48 h to 0.5 μM iAsIII, MAsIII or DMAsIII
and in control (Ctrl), unexposed islets; mean and standard error for 4 samples per treatment
(15 islets per sample) are shown.
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Reversibility of the inhibition of glucose stimulated insulin secretion by trivalent arsenicals:
Glucose-stimulated insulin secretion by control (Ctrl) pancreatic islets and by islets exposed
for 24 h to 2 μM iAsIII, 0.5 μM MAsIII or 0.5 μM DMAsIII before (E) and after (E+R) 24-
hour recovery in As-free medium; mean and standard error for 4–10 assays with 15 islets per
assay are shown (*p<0.001 for differences between exposed and the corresponding control
islets; †p<0.01 and ††p<0.0005 for differences between E+R and the corresponding E groups
of islets treated with arsenicals).
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